Skip to main content
TipRanks
Go Ultimate75% OFF

AlzChem Group AG (0ACT) Q2 2026 Earnings Report

2 Followers

GB:0ACT Q2 2026 EPS Results

Actual EPS
EUR 1.66
Consensus EPS
EUR 1.66
Beat/Miss
Met expectations
One Year Ago EPS
EUR 1.57

GB:0ACT Q2 2026 Revenue Results

Actual Revenue
EUR 155.25M
Expected Revenue
EUR 147.20M
Beat/Miss
Beat by +EUR 8.05M
YoY Revenue Growth
+8.66%

Earnings Announcement Details

Quarter
Q2 2026
Date
07/30/2026
Time
Before Open
Conference Call
Thursday, July 30, 2026
GB:0ACT Upcoming Earnings

AlzChem Group AG's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 30, 2026|% Change Since:-19.08%|
Earnings Call Sentiment|Positive

The call conveyed a broadly positive operational and financial picture: revenue and EBITDA growth, margin expansion, strong Specialty Chemicals momentum, secured financing and clear progress on strategic capacity expansions (Germany and U.S.). Counterbalancing risks include a weak Basics & Intermediates/fertilizer market, one-off refurbishment costs (~EUR 10 million) and timing-related cash/prepayment effects that may soften Q3 and weigh on H2 EBITDA sequencing. Management reaffirmed FY 2026 guidance (sales ~EUR 600m, EBITDA ~EUR 126m), reflecting confidence in underlying drivers while acknowledging near-term headwinds and ramp-up costs.

Company Guidance

The company confirmed full‑year 2026 guidance of roughly EUR 600 million in sales and about EUR 126 million in EBITDA (implying ~7% sales growth and ~8% EBITDA growth vs. prior year), noting that H1 delivered EUR 304 million sales and EUR 64.5 million EBITDA (H1 EBITDA margin 21.2% vs. 19.6% prior year) with Specialty Chemicals driving performance (H1 specialty sales EUR 214 million, EBITDA ~EUR 64 million, margin ~30%). Management warned Q3 may be softer after some H1 revenue was pulled forward but expects the new nitroguanidine capacity to start contributing in Q4; one‑off furnace refurbishment costs are ~EUR 10 million this year, operating cash flow was EUR 51 million in H1, net income EUR 35 million, equity ratio 40.3%, and a EUR 100 million growth financing package (EUR 80 million disbursed, EUR 20 million committed) was secured.

  • Group revenue and earnings growthGroup revenue increased 6% year-on-year to EUR 304.0 million in H1 2026. EBITDA rose 14% to EUR 64.5 million and EBITDA margin expanded from 19.6% to 21.2%. Net income increased ~14% to EUR 35 million (EPS up similarly).
  • Specialty Chemicals: clear growth and margin driverSpecialty Chemicals revenue grew 10% year-on-year to EUR 214 million, contributing 70% of group sales (up from 67%). Segment EBITDA increased ~19% to approx. EUR 64 million and the segment EBITDA margin expanded to close to 30%, driven by higher volumes, favorable mix (ingredients, Creapure/Creavitalis, nitroguanidine) and high capacity utilization.
  • Strong balance sheet and cash/financing positionSecured a EUR 100 million growth financing package (EUR 80 million disbursed, EUR 20 million committed). Equity increased by EUR 40 million, equity ratio ~40.3%. Operating cash flow was EUR 51 million (adjusted improvement after accounting for lower customer grants). EUR 30 million of new term loans were used to optimize repayment of near-term maturities.
  • Progress on strategic expansion projectsMajor capacity projects reached key milestones: carbide furnace refurbishment nearing completion (recommissioning planned in Q3, precise start-up in September); nitroguanidine expansion and new guanidine facility in Germany entered commissioning/start-up; U.S. site decision (Bushy Park, SC) made for nitroguanidine with feed and permitting underway, construction targeted in 2027 and ramp to production expected from 2029 with turnover potential near EUR 100 million.
  • Operational resilience and regional growthRevenue increases driven by both volumes and improved pricing, with major regional sales growth in Europe and the U.S. Specialty business demonstrated resilience amid geopolitical tensions; no current supply chain or transportation bottlenecks reported.
  • Improving signs in Basics & Intermediates (Q2)While H1 Basics & Intermediates revenue declined 4% to EUR 75.4 million, Q2 showed a 9% year-on-year recovery to EUR 38.7 million, supported by higher volumes in the steel/ metallurgical business and early signs of stabilization.

GB:0ACT Earnings History

GB:0ACT earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)―-1.66――
Oct 29, 20262026 (Q3)1.431.341.61-16.77% (-0.27)
Jul 30, 20262026 (Q2)1.661.661.575.73% (+0.09)
Apr 30, 20262026 (Q1)1.771.771.4422.92% (+0.33)
Feb 27, 20262025 (Q4)1.661.661.4911.41% (+0.17)
Oct 30, 20252025 (Q3)1.591.611.2231.97% (+0.39)
Jul 30, 20252025 (Q2)1.571.571.4111.35% (+0.16)
Apr 30, 20252025 (Q1)―1.441.220.00% (+0.24)
Feb 28, 20252024 (Q4)1.171.491.0837.33% (+0.41)
Nov 07, 20242024 (Q3)1.22-0.85―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed